Business
Six-Year Natural History Comparison with Mirum’s LIVMARLI (maralixibat) Demonstrates Event-Free Survival and Transplant-Free Survival in Patients with Alagille Syndrome
- Results demonstrate statistically significant improvement in six-year event-free survival
About this update from Mirum Pharmaceuticals, Inc.
[{"type":"text","content":"\n- Results demonstrate statistically significant improvement in six-year event-free survival (p","length":157,"tagName":"div"}]